clinical trial · NCT06031805
PRostate Olaparib Real World Evidence Study
AstraZeneca·—·recruiting·n = 300
Metastatic Castration-resistant Prostate Cancer
brief summary
This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
started
Oct 11, 2023
primary completion
Oct 13, 2028
completion
Oct 13, 2028
last updated
Apr 21, 2026
official title
A French Observational Longitudinal Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol